Cloud-Clone AGE kit used in phase 3 albumin trial published in Signal Transduction and Targeted Therapy

A Beijing Friendship Hospital team used Cloud-Clone’s AGE ELISA kit in a phase 3 trial of recombinant human serum albumin for cirrhotic ascites, published Sept. 10, 2026 in Signal Transduction and Targeted Therapy. The study found rHSA matched plasma-derived albumin on clinical outcomes and showed lower glycation signals, underscoring the role of molecular quality in albumin assessment.

Why it matters: - The trial adds molecular-quality data to a phase 3 comparison of recombinant human serum albumin and plasma-derived human serum albumin for cirrhotic ascites. - The findings suggest albumin evaluation should go beyond dose and clinical response to include glycation and other structural changes. - Cloud-Clone’s CEB353Ge kit was part of the analytical workflow that identified those differences.

What happened: - Researchers from the Liver Research Center at Beijing Friendship Hospital, Capital Medical University, published the study on Sept. 10, 2026 in Signal Transduction and Targeted Therapy. - The multicenter, randomized, double-blind, active-controlled phase 3 trial enrolled 390 patients with cirrhotic ascites. - The study was registered as NCT06553456. - The trial compared recombinant human serum albumin, or rHSA, with plasma-derived human serum albumin, or pHSA. - The team used LC-MS profiling and Cloud-Clone’s Advanced Glycation End-product ELISA Kit, catalog CEB353Ge, to study glycation-related differences between the two products.

The details: - The trial’s dual primary endpoints showed rHSA achieved equivalent serum-albumin elevation and non-inferior ascites-relief efficacy versus pHSA. - Exploratory analysis found glycated-albumin levels fell 12.24% in the rHSA group. - Glycated-albumin levels rose 12.52% in the pHSA group. - Follow-up LC-MS work identified multiple non-enzymatic glycation sites on pHSA molecules. - rHSA produced in Pichia pastoris showed no detectable non-enzymatic glycation. - The published data showed CEB353Ge measured significantly lower AGE concentrations in rHSA than in pHSA, with P < 0.05. - Cloud-Clone describes CEB353Ge as a competitive-inhibition ELISA built to quantify AGE concentrations in complex matrices, including finished albumin drug formulations. - Cloud-Clone says the kit is validated for lot-to-lot stability and multicenter studies. - Cloud-Clone says the kit also has research applications in diabetic complications, ageing mechanisms, oxidative stress profiling and protein-therapeutic quality assessment.

Between the lines: - The study is a sign that regulators, clinicians and drug developers may pay more attention to molecular integrity when judging biologics, not just clinical performance. - The glycation findings could matter for manufacturing controls because unintended sugar-related modifications can affect half-life, immunogenicity and activity. - The publication also gives Cloud-Clone a visible real-world citation in a high-impact journal, which the company uses to support its reagent portfolio. - Cloud-Clone says its reagents have been cited in more than 42,000 SCI-indexed publications, including more than 350 studies in Nature, Science and Cell.

What's next: - The authors’ findings could support broader use of molecular-quality monitoring in albumin development and other protein therapeutics. - Cloud-Clone says it will continue developing AGE-focused reagents, including antibodies, proteins and multiplex detection platforms. - Researchers interested in the company’s AGE products can find more information at the company’s announcement.

The bottom line: - The study ties a clinical win for recombinant albumin to a more detailed read on protein glycation, and it puts Cloud-Clone’s AGE kit into a top-tier publication as part of the evidence base.